CD8A and neoplasm: Although AdjFluVx increased the proportion of DCs among APCs in the tumor (albeit less than FluVx), AdjFluVx did not augment CD8+ T cells (including tumor antigen-specific T cells) within the tumor, ultimately failing to produce the elevated T cell:B cell ratio achieved by FluVx, and instead resulting in elevated influenza virus-specific antibodies in the tumor (Fig. 6 A–E and SI Appendix, Figs. S12 and S13).